Pharmaceutical firm Biocon is likely to post a profit after tax of Rs 94 crore in the third quarter of FY12, a growth of 10% as compared to Rs 86 crore in the previous quarter.
Revenues are seen going up by 7% to Rs 552 crore from Rs 513 crore quarter-on-quarter.
EBITDA is expected to go up by 10% to Rs 152 crore in the quarter ended December FY12 versus Rs 138.5 crore in the previous quarter.
Operating profit margin is likely to be at 27.6% versus 27% during the same period.
Watch out for:
- Growth to be led by Biopharm + CRAMS
- In Q2 Biopharma grew 21% led by Statins, Immunosuppresants, Insulin + Fidaxomicin API to Optimer and within Branded formulations growth was led by diabetology which grew 46% YoY
-CRAMS has picked up
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
